237 related articles for article (PubMed ID: 20393691)
1. Antitumor efficacy of viral therapy using genetically engineered Newcastle disease virus [NDV(F3aa)-GFP] for peritoneally disseminated gastric cancer.
Song KY; Wong J; Gonzalez L; Sheng G; Zamarin D; Fong Y
J Mol Med (Berl); 2010 Jun; 88(6):589-96. PubMed ID: 20393691
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic effects of a fusogenic newcastle disease virus in treating head and neck cancer.
Li P; Chen CH; Li S; Givi B; Yu Z; Zamarin D; Palese P; Fong Y; Wong RJ
Head Neck; 2011 Oct; 33(10):1394-9. PubMed ID: 21928411
[TBL] [Abstract][Full Text] [Related]
3. Detection of free peritoneal cancer cells in gastric cancer using cancer-specific Newcastle disease virus.
Wong J; Schulman A; Kelly K; Zamarin D; Palese P; Fong Y
J Gastrointest Surg; 2010 Jan; 14(1):7-14. PubMed ID: 19902312
[TBL] [Abstract][Full Text] [Related]
4. Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma.
Silberhumer GR; Brader P; Wong J; Serganova IS; Gönen M; Gonzalez SJ; Blasberg R; Zamarin D; Fong Y
Mol Cancer Ther; 2010 Oct; 9(10):2761-9. PubMed ID: 20858727
[TBL] [Abstract][Full Text] [Related]
5. Development of the oncolytic virus, CF33, and its derivatives for peritoneal-directed treatment of gastric cancer peritoneal metastases.
Yang A; Zhang Z; Chaurasiya S; Park AK; Jung A; Lu J; Kim SI; Priceman S; Fong Y; Woo Y
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37019471
[TBL] [Abstract][Full Text] [Related]
6. Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells.
Jiang K; Song C; Kong L; Hu L; Lin G; Ye T; Yao G; Wang Y; Chen H; Cheng W; Barr MP; Liu Q; Zhang G; Ding C; Meng S
BMC Cancer; 2018 Jul; 18(1):746. PubMed ID: 30021550
[TBL] [Abstract][Full Text] [Related]
7. Regional administration of oncolytic Echovirus 1 as a novel therapy for the peritoneal dissemination of gastric cancer.
Haley ES; Au GG; Carlton BR; Barry RD; Shafren DR
J Mol Med (Berl); 2009 Apr; 87(4):385-99. PubMed ID: 19139835
[TBL] [Abstract][Full Text] [Related]
8. Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy.
Cheng X; Wang W; Xu Q; Harper J; Carroll D; Galinski MS; Suzich J; Jin H
J Virol; 2016 Jun; 90(11):5343-5352. PubMed ID: 27009956
[TBL] [Abstract][Full Text] [Related]
9. A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma.
Abdullahi S; Jäkel M; Behrend SJ; Steiger K; Topping G; Krabbe T; Colombo A; Sandig V; Schiergens TS; Thasler WE; Werner J; Lichtenthaler SF; Schmid RM; Ebert O; Altomonte J
J Virol; 2018 Dec; 92(23):. PubMed ID: 30232179
[TBL] [Abstract][Full Text] [Related]
10. Engineered newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma.
Altomonte J; Marozin S; Schmid RM; Ebert O
Mol Ther; 2010 Feb; 18(2):275-84. PubMed ID: 19809404
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the virulence for chickens of Newcastle Disease virus with an engineered multi-basic cleavage site in the fusion protein and disrupted V protein gene.
de Graaf JF; van Nieuwkoop S; de Meulder D; Lexmond P; Kuiken T; Groeneveld D; Fouchier RAM; van den Hoogen BG
Vet Microbiol; 2022 Jun; 269():109437. PubMed ID: 35472508
[TBL] [Abstract][Full Text] [Related]
12. Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation.
Fournier P; Bian H; Szeberényi J; Schirrmacher V
Methods Mol Biol; 2012; 797():177-204. PubMed ID: 21948477
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic therapy of a recombinant Newcastle disease virus D90 strain for lung cancer.
Chai Z; Zhang P; Fu F; Zhang X; Liu Y; Hu L; Li X
Virol J; 2014 May; 11():84. PubMed ID: 24885546
[TBL] [Abstract][Full Text] [Related]
14. NDV-D90 suppresses growth of gastric cancer and cancer-related vascularization.
Sui H; Wang K; Xie R; Li X; Li K; Bai Y; Wang X; Bai B; Chen D; Li J; Shen B
Oncotarget; 2017 May; 8(21):34516-34524. PubMed ID: 28388537
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic effect of wild-type Newcastle disease virus isolates in cancer cell lines in vitro and in vivo on xenograft model.
Yurchenko KS; Zhou P; Kovner AV; Zavjalov EL; Shestopalova LV; Shestopalov AM
PLoS One; 2018; 13(4):e0195425. PubMed ID: 29621357
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological modulation of autophagy enhances Newcastle disease virus-mediated oncolysis in drug-resistant lung cancer cells.
Jiang K; Li Y; Zhu Q; Xu J; Wang Y; Deng W; Liu Q; Zhang G; Meng S
BMC Cancer; 2014 Jul; 14():551. PubMed ID: 25078870
[TBL] [Abstract][Full Text] [Related]
17. Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy.
Elankumaran S; Chavan V; Qiao D; Shobana R; Moorkanat G; Biswas M; Samal SK
J Virol; 2010 Apr; 84(8):3835-44. PubMed ID: 20147405
[TBL] [Abstract][Full Text] [Related]
18. Construction of recombinant Newcastle disease virus Italien strain for oncolytic virotherapy of tumors.
Wei D; Sun N; Nan G; Wang Y; Liu HQ; Peeters B; Chen ZN; Bian H
Hum Gene Ther; 2012 Jul; 23(7):700-10. PubMed ID: 22372930
[TBL] [Abstract][Full Text] [Related]
19. Genetically engineered Newcastle disease virus for malignant melanoma therapy.
Zamarin D; Vigil A; Kelly K; García-Sastre A; Fong Y
Gene Ther; 2009 Jun; 16(6):796-804. PubMed ID: 19242529
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance.
Schirrmacher V
Expert Opin Biol Ther; 2015; 15(12):1757-71. PubMed ID: 26436571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
